Over USD 36 million of anti-rabies and anti-venom vaccines have been imported by Pakistan from India due to lack of manufacturing capacity in the country, according to a media report.
The Nation newspaper on Thursday reported that in the last 16 months, Pakistan imported anti-rabies and anti-venom vaccines worth over Rs 250 crores (USD 36 million) from India.
The Ministry of National Health Services (NHS) submitted the statistics in the Senate Standing Committee after Senator Rehman Malik asked about the quantity and value of medicines being imported from India.
He also sought a reply on the capacity of government departments for manufacturing the vaccines.
In its reply, NHS said that both anti-rabies and anti-venom serum were manufactured in Pakistan by the National Institute of Health, while a private company also manufactured anti-venom serum locally, the report said.
However, the capacity of both manufacturers was not enough to fulfil the demand due to which the vaccines are imported by duly-approved registration holders of these products from India.
Pakistan was buying the vaccines despite the chill in bilateral ties, especially after the Pulwama terror attack by a suicide bomber belonging to Pakistan-based Jaish-e-Mohammed terrorist.
The report submitted by NHS also revealed that there was a gap in demand and supply of vaccines in different regions of the country.
Senator Malik suggested that it must be made mandatory for local manufacturers to produce these vaccines as Pakistan is self-sufficient in medical raw material and that vaccines manufactured here will be much more affordable.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
